Online citations, reference lists, and bibliographies.
← Back to Search

Updates On Phase1b/2 Trial Of The Indoleamine 2,3-dioxygenase Pathway (IDO) Inhibitor Indoximod Plus Checkpoint Inhibitors For The Treatment Of Unresectable Stage 3 Or 4 Melanoma.

Y. Zakharia, J. Drabick, S. Khleif, R. McWilliams, D. Munn, C. Link, N. Vahanian, E. Kennedy, M. Shaheen, O. Rixe, M. Milhem
Published 2016 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
3075Background: IDO is an enzyme that catalyzes tryptophan to kynurenine. Tryptophan depletion enhances the function of the suppressive Treg and inhibits the effector T cells. Kynurenine metabolite...



This paper is referenced by
10.4137/IJTR.S38355
The Kynurenine Pathway Is a Double-Edged Sword in Immune-Privileged Sites and in Cancer: Implications for Immunotherapy
J. Routy (2016)
10.1016/J.CLSC.2017.06.003
Is It Better to Use Ipilimumab Combined With a PD-1 Inhibitor or a PD-1 Inhibitor Alone as Initial Immunotherapy in Patients With Metastatic Melanoma?
Lucas M.D. Espíndola (2017)
10.1007/s00280-018-3518-7
Role of immunotherapy in bladder cancer: past, present and future
S. Butt (2018)
10.1007/s12032-018-1080-0
The role of tumor-infiltrating lymphocytes (TILs) as a predictive biomarker of response to anti-PD1 therapy in patients with metastatic non-small cell lung cancer or metastatic melanoma
Anton Uryvaev (2018)
10.1016/J.JONS.2017.04.001
Indoleamine 2,3-dioxygenase (IDO): Only an enzyme or a checkpoint controller?
C. Bilir (2017)
10.1016/j.trsl.2017.11.002
The role of macrophage phenotype in regulating the response to radiation therapy
Xiaoshan Shi (2018)
10.1158/1078-0432.CCR-16-2318
Strategies for Increasing Pancreatic Tumor Immunogenicity
Burles A. Johnson (2017)
10.1038/icb.2016.126
Targeting cancer‐related inflammation in the era of immunotherapy
K. Nakamura (2017)
10.1186/s13045-017-0552-6
Cancer immunotherapy beyond immune checkpoint inhibitors
Julian A. Marin-Acevedo (2018)
10.1097/PPO.0000000000000299
Clinical Development of PD-1 in Advanced Melanoma
R. Munhoz (2018)
10.1038/s41568-019-0106-z
Immune control by amino acid catabolism during tumorigenesis and therapy
H. Lemos (2019)
10.1016/j.bbcan.2018.12.002
Immune checkpoint blockade and its combination therapy with small-molecule inhibitors for cancer treatment.
Manni Wang (2019)
10.1016/j.critrevonc.2018.11.002
Advanced stage melanoma therapies: Detailing the present and exploring the future.
C. Luther (2019)
10.1186/s13045-018-0582-8
Next generation of immune checkpoint therapy in cancer: new developments and challenges
Julian A. Marin-Acevedo (2018)
10.3389/fonc.2020.00051
Immunometabolic Network Interactions of the Kynurenine Pathway in Cutaneous Malignant Melanoma
Soudabeh Rad Pour (2020)
10.32948/auo.2019.09.04
Immunotherapy Landscape in Prostate Cancer: Successes, Failures and Promises
S. Butt (2019)
Semantic Scholar Logo Some data provided by SemanticScholar